Reuters logo
7 months ago
BRIEF-Auris Medical expands clinical development pipeline for vertigo treatment
February 3, 2017 / 12:15 PM / 7 months ago

BRIEF-Auris Medical expands clinical development pipeline for vertigo treatment

Feb 3 (Reuters) - Auris Medical Holding Ag

* Auris Medical expands clinical development pipeline with intranasal betahistine for the treatment of meniere's disease and vestibular vertigo

* Auris Medical Holding Ag - under product code am-125, to develop betahistine dihydrochloride in spray formulation

* Auris Medical Holding Ag - entered into an agreement with otifex therapeutics pty. ltd. To purchase various assets related to intranasal betahistine

* Auris Medical Holding Ag - plans to initiate a second phase 1 trial for intranasal betahistine in 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below